Learning Management System

Skip Over Navigation

Course Description



TB-299 3HP: Enough "Horse Power" to drive the national TB Infection agenda?


Enrollment DeadlineSectionCourse FormatStart/End Dates Details Instructor(s)Speakers
Enroll
Ongoing
Webinar Online Ongoing
David Ashkin, MD   David Griffith, MD   Andrey Borisov, MD   Neela Goswami, MD, MPH  


Course Description

Objectives:

  • Interpret current national TB control priorities in the context of the recent CDC recommendations for use of 3HP to achieve optimal care for patients with latent TB infection.  
  • List important pharmacological aspects of rifapentine alone and in combination with INH including toxicities to prevent primary drug resistance in patients with TB disease.
  • Outline the evidence for the efficacy and safety of 3HP treatment of latent TB to apply in the care of patients with latent TB infection.
  • Investigate alternative latent TB treatment strategies for patients who are not candidates for 3HP for the purpose of improving their treatment outcomes.

For the webinar overview:  https://sntc.medicine.ufl.edu//Content/Webinars/SupportingDocs//3HP%20Webinar_Overview%20Slides.pdf

Borisov's slides:  https://sntc.medicine.ufl.edu//Content/Webinars/SupportingDocs//3HP%20Webinar_Borisov.pdf

Griffith slides:  https://sntc.medicine.ufl.edu//Content/Webinars/SupportingDocs//3HP%20Webinar_Griffith.pdf

Q&A:  https://sntc.medicine.ufl.edu//Content/Webinars/SupportingDocs//3HP%20Webinar%20Questions.docx

Transcript:  https://sntc.medicine.ufl.edu//Content/Webinars/SupportingDocs//3HP%20Enough%20Horse%20Power%20to%20drive%20the%20national%20TB%20Infection%20agenda.pdf

 

 

Keywords:  TB, tuberculosis, TB disease, MTB, Mycobacterium tuberculosis, MTB complex, LTBI, latent TB infection, TB infection, 3HP, 12 dose regimen for latent TB infection, rifapentine, isoniazid

Prerequisites

None

Course Competencies

There are no competencies currently assigned to this course